Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Experts outline clinically grounded strategies to manage cost, improve outcomes and coordinate care across benefits

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years...

Home News & Insights Research & publications Archived Content High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel...